Perospirone information

Perospirone
Clinical data
Trade names	Lullan
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	92%
Metabolism	Hepatic
Elimination half-life	1.9–2.5 hours
Excretion	Renal (0.4% as unchanged drug)
Identifiers
	IUPAC name (3aS,7aR)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione;
CAS Number	150915-41-6 ;
PubChem CID	115368;
IUPHAR/BPS	7556;
ChemSpider	16737064 ;
UNII	N303OK87DT;
CompTox Dashboard (EPA)	DTXSID2048163 ;
Chemical and physical data
Formula	C23H30N4O2S
Molar mass	426.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4N(CCCCN1CCN(CC1)C\3=N\SCc2ccccc2/3)C(=O)[C@@H]5CCCC[C@H]45;
	InChI InChI=1S/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+ ; Key:GTAIPSDXDDTGBZ-OYRHEFFESA-N ;
	(what is this?) (verify)

Perospirone (Lullan) is an atypical antipsychotic of the azapirone family.^[1] It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.^[3]^[4]

^ ^a ^b ^c ^d ^e Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136. S2CID 262520276.
^ Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (August 2004). "Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response". Therapeutic Drug Monitoring. 26 (4): 361–365. doi:10.1097/00007691-200408000-00004. PMID 15257064. S2CID 43362616.
^ de Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs. 3 (1): 121–129. PMID 12054062.
^ "Now on the Market : New Antipsychotic "Lullan® Tablets" - serotonin-dopamine antagonist originated in Japan". Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma. 8 February 2001. Archived from the original on 24 February 2006.

[CNS_Drugs-1] Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136. S2CID 262520276.

[2] Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (August 2004). "Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response". Therapeutic Drug Monitoring. 26 (4): 361–365. doi:10.1097/00007691-200408000-00004. PMID 15257064. S2CID 43362616.

[pmid12054062-3] Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs. 3 (1): 121–129. PMID 12054062.

[urlSumitomo_Pharmaceuticals_2001_|_News_Release_|_Dainippon_Sumitomo_Pharma-4] "Now on the Market : New Antipsychotic "Lullan® Tablets" - serotonin-dopamine antagonist originated in Japan". Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma. 8 February 2001. Archived from the original on 24 February 2006.

Perospirone information

and 27 Related for: Perospirone information

Perospirone

Isothiazole

MDMA

Coprophagia

Ketamine

Piperazine

Antipsychotic

LSD

Cannabidiol

Phencyclidine

Aripiprazole

Modafinil

Bupropion

Dopamine

Amitriptyline

Diphenhydramine

Trazodone

Buspirone

Domperidone

Haloperidol

Prochlorperazine

Ondansetron

Tyrosine

Metoclopramide

Guanfacine

Tricyclic antidepressant

Ibogaine